New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC phase III trial have shown that triple therapy targeting BRAF mutations in progressive metastatic colorectal tumours significantly improved overall survival and objective response compared to standard care. (1)
Cancer took more than 8.7 million years of life and $94.4 billion in lost earnings among people ages 16 to 84 in the United States in 2015. The calculation comes from a new report by American Cancer Society researchers that appears early online in JAMA Oncology.
On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
A microfluidic chip. Credit: Alain Herzog (EPFL)
Researchers at EPFL have developed a method to stimulate human stem cells to organize themselves into ordered layers of different cell types.
Tre beagles hanno dimostrato di essere in grado di identificare con successo il cancro ai polmoni attraverso l'odore, un primo passo per identificare specifici biomarcatori per la malattia. I ricercatori affermano che queste capacità dei cani possono portare allo sviluppo di mezzi efficaci, sicuri e poco costosi per lo screening dei tumori di massa.
Continua a leggere "Tumore al polmone: i cani lo scoprono dall' odore nel 97% dei casi" »
Higher coronary artery calcium levels in middle-age were associated with structural heart abnormalities linked to future heart failure, particularly among blacks, according to new research in Circulation: Cardiovascular Imaging, an American Heart Association journal.
The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®* (ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab - an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody - on SLE disease activity at one-year, but also show a reduction in the rate of severe flares.
The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data this week from PsABio – its ongoing, real-world study of nearly 1,000 people with psoriatic arthritis, who have started treatment with either Stelara (ustekinumab) or a Tumour Necrosis Factor inhibitor (TNFi).1
Continua a leggere "Effective PsA treatment should target more than skin and joints #EULAR2019" »
How slow—or fast—older individuals with blood cancers are able to walk four meters (about 13 feet) holds critical information about their overall health and strongly predicts survival and unplanned hospital visits regardless of age, cancer or treatment type, or other factors, according to a new study published today in Blood. The association was strongest in those with non-Hodgkin lymphoma.
Continua a leggere "Walking Speed Predicts Clinical Outcomes in Older Adults with Blood Cancers" »
Bristol-Myers Squibb Company ha annunciato i risultati aggiornati degli studi che hanno valutato nivolumab e ipilimumab, in monoterapia o in combinazione, in pazienti con melanoma avanzato o metastatico. Queste analisi sono state presentate lunedì 3 giugno (Abstract 9533, 9568 e 9551) al Congresso dell’American Society of Clinical Oncology (ASCO) in corso a Chicago.
